| Term 
 
        | Sodium levothyroxine (Synthroid-T4) |  | Definition 
 
        | Hormone replacement therapy for hypothyroidism |  | 
        |  | 
        
        | Term 
 
        | Sodium liothyronine (Cytomel-T3) |  | Definition 
 
        | Hormone replacement therapy for hypothyroidism 4 times as potent as T4, more rapid onset of action, same efficacy
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Used in the treatment of hyperthyroidism Inhibits peroxidase enzyme system responsible for synthesis of T4 and T3
 Inhibits conversion of T4 to T3
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Releases gamma rays & ablates 80-90% of the thyroid, surgical removal of any remnants Gamma rays are localized in the thyroid only
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Corticosteroid, immunosuppresant Overuse may result Cushing syndrome
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Treatment for Conn's syndrome Suppresses ACTH release from the pituitary
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cortisol in oral, intravenous or topical forms Prescribed for use in several situations
 Used as cortisol replacement in the event of surgery to remove pituitary or adrenal tumour
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Synthetic cortisteroid Mineralcorticoid > glucocorticoid
 Used as aldosterone replacement in adrenal insufficiency and adrenal hyperplasia
 First line treatment for orthostatic intolerance and Postural Tachycardia Syndrome
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive antagonist of the mineralcorticoid receptor Used mainly as a potassium sparing diuretic & antihypertensive
 Also reduced elevated or unwanted androgen activity
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive antagonist of the mineralcorticoid receptor More selective than spirolactone (no androgen effects)
 Marketed for the reduction of cardiovascualr risk in patients following myocardial infarction
 |  | 
        |  |